299.17
price down icon2.47%   -7.59
after-market Dopo l'orario di chiusura: 299.17
loading
Precedente Chiudi:
$306.76
Aprire:
$309.83
Volume 24 ore:
360.08K
Relative Volume:
1.06
Capitalizzazione di mercato:
$6.64B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-11.91
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
-14.21%
1M Prestazione:
+4.98%
6M Prestazione:
-8.83%
1 anno Prestazione:
+6.07%
Intervallo 1D:
Value
$298.79
$312.00
Intervallo di 1 settimana:
Value
$298.79
$351.20
Portata 52W:
Value
$200.63
$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
Nome
Madrigal Pharmaceuticals Inc
Name
Telefono
404-380-9263
Name
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
Dipendente
528
Name
Cinguettio
@MadrigalPharma
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
MDGL's Discussions on Twitter

Confronta MDGL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
299.17 6.81B 0 -518.67M -438.32M -25.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-28 Aggiornamento B. Riley Securities Neutral → Buy
2025-02-27 Reiterato H.C. Wainwright Buy
2024-06-28 Iniziato Cantor Fitzgerald Neutral
2024-06-11 Iniziato Wolfe Research Outperform
2024-04-22 Iniziato BofA Securities Underperform
2024-03-15 Aggiornamento B. Riley Securities Sell → Neutral
2024-03-06 Iniziato Citigroup Buy
2024-02-26 Downgrade B. Riley Securities Neutral → Sell
2022-12-20 Reiterato Oppenheimer Outperform
2022-12-19 Reiterato H.C. Wainwright Buy
2022-12-19 Reiterato Piper Sandler Overweight
2022-12-19 Aggiornamento Raymond James Underperform → Mkt Perform
2022-07-08 Downgrade B. Riley Securities Buy → Neutral
2021-10-07 Iniziato Jefferies Buy
2021-08-06 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-05-20 Ripresa Goldman Buy
2020-11-24 Ripresa Evercore ISI Outperform
2020-11-06 Reiterato H.C. Wainwright Buy
2020-07-31 Iniziato Piper Sandler Overweight
2020-06-05 Iniziato BMO Capital Markets Market Perform
2020-05-05 Iniziato Chardan Capital Markets Buy
2020-01-30 Iniziato Canaccord Genuity Buy
2020-01-09 Aggiornamento UBS Neutral → Buy
2019-11-07 Reiterato H.C. Wainwright Buy
2019-06-25 Iniziato Stifel Hold
2019-06-10 Aggiornamento B. Riley FBR Neutral → Buy
2019-02-28 Reiterato H.C. Wainwright Buy
2019-02-22 Iniziato SVB Leerink Outperform
2019-01-23 Iniziato UBS Neutral
2018-12-14 Iniziato Wolfe Research Outperform
2018-12-12 Iniziato B. Riley FBR Neutral
2018-11-19 Downgrade Raymond James Mkt Perform → Underperform
2018-11-16 Aggiornamento Evercore ISI In-line → Outperform
2018-09-04 Iniziato Citigroup Buy
2018-08-06 Downgrade Goldman Buy → Neutral
2018-06-28 Iniziato Raymond James Mkt Perform
Mostra tutto

Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie

pulisher
Jul 24, 2025

Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Madrigal Pharmaceuticals: Strengthened Financial Position and Promising Pipeline Expansion Drive Buy Rating - TipRanks

Jul 24, 2025
pulisher
Jul 23, 2025

Madrigal Pharmaceuticals secures $500M credit facility from Blue Owl - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Madrigal Pharmaceuticals Inc. stock priceHigh-velocity gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Madrigal Pharmaceuticals Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Madrigal Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Madrigal Pharmaceuticals Inc. stockSuperior portfolio returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal's $500M Financing: Cementing Leadership in the High-Growth MASH Market - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500M Credit Facility - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals (MDGL) Secures $500 Million Credit Facility - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal secures $500 million credit facility to advance MASH pipeline By Investing.com - Investing.com Nigeria

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500 Million Senior Secured Credit Facility to Enhance MASH Pipeline and Support Strategic Expansion - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Citizens JMP reiterates Madrigal stock rating on strong Rezdiffra uptake By Investing.com - Investing.com Canada

Jul 22, 2025
pulisher
Jul 21, 2025

10 Most Undervalued Healthcare Stocks To Buy According To Analysts - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Madrigal Pharmaceuticals Secures Key Patent for Rezdiffra, Extending Market Protection to 2044 - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

Madrigal gains after Rezdiffra patent win - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN

Jul 19, 2025
pulisher
Jul 17, 2025

Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals receives notice of allowance for Rezdiffra patent - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals Surges to 222nd in Daily Rankings with $451 Million Turnover - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals: Strong Surge or Overpriced? - StocksToTrade

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals stock price target raised by Oppenheimer on patent news - Investing.com Canada

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal’s Surge: Breakthrough in Liver Treatment? - timothysykes.com

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals Soars: Is It Time to Buy?​ - StocksToTrade

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals (MDGL) Surges Over 12% in Market Gains - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals (MDGL) Soars on Rezdiffra Patent Approval - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal gains after Rezdiffra patent win (MDGL:NASDAQ) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal stock jumps as patent protection for MASH treatment extended By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal stock jumps as patent protection for MASH treatment extended - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal receives patent allowance for MASH treatment Rezdiffra By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

Why Madrigal Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals (MDGL) Secures Patent for Rezdiffra Use - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal receives patent allowance for MASH treatment Rezdiffra - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals Announces FDA Patent Allowance for Rezdiffra™ Providing Protection Through September 2044 - Quiver Quantitative

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals Receives Notice of Allowance from - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom) - Yahoo Finance

Jul 16, 2025

Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):